Manila Times Business
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1-4, 2026 in Munich, Germany. The program will include two oral presentations from Pha
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
These Are Australia's Best Workplaces in Finance and Insurance
4h ago
ATLATL and Samsung Bioepis Launch 'Samsung Bioepis Innovation Prize C-Lab Outside' to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific
4h ago
TWL Introduces Virtual Tirzepatide Assessment Program for Eligible Weight-Management Patients
4h ago
OCI N.V. confirms receipt of unsolicited voluntary cash offer from NNS of EUR 4.10 per Share
4h ago